Biren Amin
Stock Analyst at Piper Sandler
(1.19)
# 3,553
Out of 4,876 analysts
59
Total ratings
37.25%
Success rate
-15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTX Context Therapeutics | Reiterates: Overweight | $4.5 → $4 | $0.65 | +516.33% | 1 | Jun 26, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Neutral | $70 → $36 | $17.43 | +106.54% | 8 | Jun 16, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $20 → $17 | $4.76 | +257.14% | 2 | May 16, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Overweight | $9 → $7 | $1.20 | +483.33% | 3 | May 14, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $46 → $63 | $45.11 | +39.66% | 2 | Apr 30, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Overweight | $38 → $51 | $30.65 | +66.37% | 1 | Apr 14, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $38 | $12.97 | +192.98% | 1 | Mar 31, 2025 | |
| ELEV Elevation Oncology | Downgrades: Neutral | $10 → $0.7 | $0.38 | +83.63% | 2 | Mar 21, 2025 | |
| MNPR Monopar Therapeutics | Assumes: Overweight | $76 | $34.73 | +118.83% | 1 | Mar 19, 2025 | |
| CMPX Compass Therapeutics | Initiates: Overweight | $12 | $2.57 | +366.93% | 1 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $71 | $26.99 | +163.06% | 2 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $4 | $4.21 | -4.99% | 3 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $7.91 | +342.48% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $9.05 | +132.04% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $115 | $65.82 | +74.72% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $17.79 | +79.88% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $5.02 | -40.24% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $9.44 | +58.90% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $1.28 | +5,390.20% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $0.38 | +13,321.05% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $3.98 | +503.02% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $2.45 | +1,287.76% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $4.95 | +10,001.01% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $5.64 | +148.23% | 1 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $657 → $691 | $523.59 | +31.97% | 2 | Jun 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $2.42 | +314.08% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $22.61 | +346.71% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $126.57 | -45.48% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $446.07 | -65.25% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $1.76 | +7,627.27% | 4 | Mar 6, 2017 |
Context Therapeutics
Jun 26, 2025
Reiterates: Overweight
Price Target: $4.5 → $4
Current: $0.65
Upside: +516.33%
Sarepta Therapeutics
Jun 16, 2025
Downgrades: Neutral
Price Target: $70 → $36
Current: $17.43
Upside: +106.54%
Solid Biosciences
May 16, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $4.76
Upside: +257.14%
Allogene Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $9 → $7
Current: $1.20
Upside: +483.33%
BridgeBio Pharma
Apr 30, 2025
Maintains: Overweight
Price Target: $46 → $63
Current: $45.11
Upside: +39.66%
LENZ Therapeutics
Apr 14, 2025
Maintains: Overweight
Price Target: $38 → $51
Current: $30.65
Upside: +66.37%
Centessa Pharmaceuticals
Mar 31, 2025
Initiates: Overweight
Price Target: $38
Current: $12.97
Upside: +192.98%
Elevation Oncology
Mar 21, 2025
Downgrades: Neutral
Price Target: $10 → $0.7
Current: $0.38
Upside: +83.63%
Monopar Therapeutics
Mar 19, 2025
Assumes: Overweight
Price Target: $76
Current: $34.73
Upside: +118.83%
Compass Therapeutics
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $2.57
Upside: +366.93%
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $26.99
Upside: +163.06%
Jan 30, 2025
Downgrades: Neutral
Price Target: $34 → $4
Current: $4.21
Upside: -4.99%
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $7.91
Upside: +342.48%
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $9.05
Upside: +132.04%
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $65.82
Upside: +74.72%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $17.79
Upside: +79.88%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $5.02
Upside: -40.24%
Jun 21, 2024
Maintains: Overweight
Price Target: $15
Current: $9.44
Upside: +58.90%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $1.28
Upside: +5,390.20%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $0.38
Upside: +13,321.05%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $3.98
Upside: +503.02%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $2.45
Upside: +1,287.76%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $4.95
Upside: +10,001.01%
Jul 24, 2020
Initiates: Buy
Price Target: $14
Current: $5.64
Upside: +148.23%
Jun 12, 2020
Maintains: Buy
Price Target: $657 → $691
Current: $523.59
Upside: +31.97%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $2.42
Upside: +314.08%
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $22.61
Upside: +346.71%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $126.57
Upside: -45.48%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $446.07
Upside: -65.25%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $1.76
Upside: +7,627.27%